Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A CONTROLLED TRIAL OF ONDANSETRON, A 5-HT3 ANTAGONIST, IN BENZODIAZEPINE DISCONTINUATION
Autore:
ROMACH MK; KAPLAN HL; BUSTO UE; SOMER G; SELLERS EM;
Indirizzi:
WOMENS COLL HOSP,DEPT PSYCHIAT,76 GRENVILLE ST TORONTO ON M5S 1B2 CANADA UNIV TORONTO,DEPT PHARMACOL TORONTO ON CANADA UNIV TORONTO,DEPT MED TORONTO ON CANADA UNIV TORONTO,DEPT PSYCHIAT TORONTO ON CANADA UNIV TORONTO,FAC PHARM TORONTO ON CANADA ADDICT RES FDN TORONTO ON M5S 2S1 CANADA
Titolo Testata:
Journal of clinical psychopharmacology
fascicolo: 2, volume: 18, anno: 1998,
pagine: 121 - 131
SICI:
0271-0749(1998)18:2<121:ACTOOA>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
TERM THERAPEUTIC USE; PANIC DISORDER; CARBAMAZEPINE TREATMENT; WITHDRAWAL SYMPTOMS; ANXIOLYTIC ACTIVITY; ANXIETY; ALPRAZOLAM; DEPENDENCE; SEROTONIN; BUSPIRONE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Science Citation Index Expanded
Science Citation Index Expanded
Citazioni:
51
Recensione:
Indirizzi per estratti:
Citazione:
M.K. Romach et al., "A CONTROLLED TRIAL OF ONDANSETRON, A 5-HT3 ANTAGONIST, IN BENZODIAZEPINE DISCONTINUATION", Journal of clinical psychopharmacology, 18(2), 1998, pp. 121-131

Abstract

Serotonin is implicated in the etiology of anxiety disorders and in the anxiolytic actions of benzodiazepines. Preclinical studies with 5-HT3 receptor antagonists, including ondansetron, show they have anxiolytic properties and that ondansetron suppresses withdrawal anxiety after abrupt discontinuation of chronic benzodiazepine treatment, We evaluated the efficacy of ondansetron as an adjunctive medication in the discontinuation of benzodiazepines in long-term users, One hundred eightpatients who had used alprazolam or lorazepam regularly for > 3 months entered, and 97 completed a randomized double-blind discontinuation treatment program during which they received either ondansetron 2 mg twice daily or placebo and flexibly tapered their benzodiazepine over aB-week period. There were no significant differences between the patients who had entered and completed treatment. Three weeks postmedication, 63% of the patients discontinued use of benzodiazepine. The percentage of reduction of benzodiazepine daily dosage at all time points inthe treatment trial was similar for the ondansetron and placebo groups, Ondansetron had no significant effects on severity of withdrawal symptoms or levels of anxiety, High placebo response may have prevented detection of an ondansetron effect. At 1 year follow-up, 68% of patients reported that they stopped using benzodiazepine. Patient characteristics were more important than ondansetron in tapered benzodiazepine discontinuation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 06:37:09